

# Index

## A

- 5-fluorouracil (5-FU), 63, 404, 406
- 5-lipoxygenase activating protein (FLAP), 366
- 5-lipoxygenase (5-LOX), 366
- 6-mercaptopurine, 63, 67, 398, 400, 407, 422, 438
- 6-methylmercaptopurine ribonucleotide, 399
- 6-thioguanine, 68, 398–399, 422
- Accessory proteins, 77–78, 81, 84–87, 97–98, 115, 140, 146
- Acute lymphocytic leukemia (ALL), 67, 278, 438
- Adenosine triphosphate (ATP)-binding cassette (ABC) family, 42, 414
  - ABCB1, 24, 41–43, 46–48, 50–56, 69, 310, 403, 408, 415–416, 420
  - ABCC1, 42–44, 46–47, 50, 56, 415
  - ABCC2, 42–43, 45–47, 50, 56, 415
  - ABCG2, 42–44, 46–48, 50–53, 55–56, 70–71
- Adenylyl cyclase (AC), 81, 113, 167
- Admixture, 31–38, 232
- Adrenal cortex, 84
- Adrenergic receptor, 94–95, 124, 127, 140, 149–153, 162, 360, 362, 364–365, 387–389
- Adverse drug reactions (ADRs), 21, 23, 274, 424
- Adverse Event Reporting System (AERS), 14–15
- Agonist, 90, 162, 363
- Agouti (Ag), 121
  - agouti-related proteins (AgRPs), 121
- Albright's hereditary osteodystrophy (AHO), 85, 87
- Albuterol, 153, 162, 360, 363–364
- Algorithm, 18, 32–33, 38
- Alleles, 67, 406, 438
  - Allele Frequencies Database, 10, 12
  - minor allele frequency (MAF), 232, 261
- Alzheimer's disease, 13, 17–18, 83, 87, 148, 164–165, 213–214, 224, 231, 233, 246–247, 257–260, 269, 273, 280, 286–292, 302, 305, 307, 317–323, 326
- American Association of Clinical Chemists (AACC), 23
- AmpliChip, 27
- Amyloid precursor protein (APP), 220, 234
- Amyloid scavengers, 257, 265–266
- Angiotensin, 88, 142–143, 165, 221, 286, 312, 317, 319, 322
  - angiotensin II receptor, 142
  - angiotensin-converting enzyme (ACE), 143, 213, 217, 304, 323
- Antagonist, 125, 128, 143, 153, 156, 227, 260, 302, 401, 427
- Anticholinergics, 360, 365
- Anticonvulsants, 24, 214, 216, 274
- Antidepressants, 24, 147–148, 214, 216, 274, 284, 293, 316, 319, 406, 408
- Antigen, 221, 265, 426, 447–449, 451–452, 464, 470, 472–475, 478
- Antigen-induced cell death (AICD), 448
- Antipsychotics, 24, 144, 146, 148, 325
- Antithrombolytics, 24
- Antiviral, 160, 389
- Anxiety, 299–300, 304, 315, 319–324
- Anxiolytics, 24, 214, 216, 274, 319
- Apolipoprotein E (APOE), 217, 221, 257–260, 286, 295, 304–305, 307, 309, 318–319, 321, 323
- Aquaporin 2 gene (AQP2), 126
- Arachidonic acid, 366
- Area under the concentration (AUC), 55–56, 67
- Arginine vasopressin (AVP), 113, 126
  - V2 vasopressin receptor (AVPR2), 113, 126–128

Array, 450, 453, 457, 459, 471, 476  
 Assays, 47, 51–52, 57, 241, 362, 386–389,  
 399, 408, 440–442, 448  
 Association study, 32, 34, 36, 231, 362  
 Assortative mating, 34–36  
 Asthma, 113, 129, 152, 162, 166, 359–367  
 Autogenomics, 27  
 Autosomal dominant hypocalcemia (ADH),  
 116–117, 119  
 Azathioprine, 24, 67–68, 398, 400, 406, 414,  
 421, 423

## B

Barter's/Gitelman's syndrome (BS/GS), 89  
 Basic Local Alignment Search Tool (BLAST),  
 4–6, 8–9, 18  
 Benzodiazepines, 24, 265, 293, 316, 320  
 Binomial conundrum, 308  
 Biochips, 21–22, 25, 29, 273  
 BioFilm, 27–28  
 Bioinformatics, 1, 2–7, 10, 13–18, 199, 255,  
 272, 325, 381, 383–384, 448, 452, 470,  
 473–474, 476  
 Bipolar disorder (BD), 146, 163,  
 187–188, 192  
 Bisulfite, 194–195, 198–199, 202–204  
 Bleeding disorder, 109, 113, 129, 156  
 Blood–brain barrier, 53–54  
 Brain-derived neurotrophic factor (BDNF),  
 187, 190, 192, 197  
 Breast cancer resistance protein (BCRP), 64, 70

## C

Caco-2, 50  
 Calcium-sensing receptor (CASR), 109, 111,  
 113, 116, 118, 139, 141, 167  
 Cancer, 9, 17, 70, 160, 228, 404, 437–441  
 breast, 64, 70  
 colon, 67, 161, 395–396, 405  
 colorectal, 404, 406  
 Cancer Genome Anatomy Project, 9  
 Candidate gene, 17–18, 71, 129, 146, 149,  
 361–362, 380–381, 383, 387, 389  
 Cardiovascular diseases, 18, 379  
 Catechol-O-methyltransferase (COMT),  
 187–188, 192, 197, 204  
 Cerebrovascular disorders, 263, 308  
 Chaperone, 222–223, 233, 240, 249–250, 253,  
 269–270  
 Chemoattractant receptor, 155  
 Chemokines, 157, 160  
 receptors, 157, 160

Chemotherapy, 25, 63–64, 67, 70, 404–405,  
 407, 437–438, 440–441, 443  
 Cholecystokinin (CCK), 160, 313  
 Cholinesterase inhibitors, 226, 260, 300, 302  
 ClustalW, 4, 6, 8  
 Clustering, 18, 33, 37, 90, 448, 451, 460–462,  
 475  
 Cognition, 214, 255, 280, 291, 302–304, 306,  
 315–316, 319, 321, 324  
 Cognitive performance, 256, 299, 315–316,  
 318, 321  
 Combination therapy, 291, 293, 303–304,  
 306, 318, 320–322, 325  
 Concentrative nucleoside transporters  
 (CNTs), 46  
 Confounding, 31, 33–38  
 Constitutively active mutants (CAMs),  
 96, 110  
 Coronary artery disease (CAD), 311, 380  
 Corticosteroids, 359–360, 367–369, 400  
 CpG islands, 193, 199–200  
 Cyclic adenosine monophosphate (cAMP), 81,  
 88, 93, 110, 113, 156, 190, 192, 219  
 cAMP response element binding protein  
 (CREB), 190, 219  
 Cyclosporine, 43–44, 50, 278, 403, 406  
 Cysteinyl leukotriene (CysLT), 79–80, 139,  
 145, 147, 150–151, 153–154, 165, 366  
 Cytochrome P450 (CYP450), 16, 23, 64, 220,  
 275–280, 287–290, 292, 397, 403, 406  
 CYP2B6, 23, 276, 281  
 CYP2C9, 23–24, 28, 274, 276, 281–283  
 CYP2C19, 23, 27–28, 274, 276, 282–283,  
 397–398, 406, 408  
 CYP2D6, 23–24, 27–28, 64–65, 213, 217,  
 223, 274, 277, 280, 282–291, 293–294,  
 304, 306–307, 315, 324, 408  
 CYP3A5, 23, 65, 274, 278, 294, 307,  
 403, 406  
 Cytokines, 152, 157, 159, 264, 452  
 Cytomegalovirus (CMV), 159

## D

Data integration, 4  
 Data mining, 18, 223, 451, 453, 462, 466, 473  
 Data quality, 460, 473  
 Data storage, 442  
 Database, 4–10, 12–18, 119, 200, 218, 270,  
 282, 361–362, 453, 462  
 Database of Interacting Proteins (DIP), 13  
 dbGaP, 5  
 dbSNP, 4–5, 9–12, 16, 361–362, 385  
 Desensitization, 90–91, 163

- Dihydropyrimidine dehydrogenase (DPD), 65, 406
- Dipeptide transporters (PEPTs), 46
- Disease-modifying antirheumatic drugs, 413–414
- DNA methylation, 187–191, 193–194, 199–200, 204, 207, 209, 222, 369
- Dopamine, 144, 227
- dopamine transporter 1 (DAT1), 187–188, 192
- receptor, 88, 144, 146–147, 163–164, 188, 197
- Dopaminergic (DAergic), 143–144, 187–188, 192
- Down syndrome, 222, 235, 246, 250, 252
- Drug absorption, 16, 53
- Drug ADME, 15
- Drug efficacy, 23, 57, 63–64, 110, 139, 141, 147, 150, 214, 271, 273, 287, 301, 326, 404–405
- Drug excretion, 360, 403
- Drug metabolism, 22–23, 55, 213–214, 216, 272, 274, 281–283, 290, 293, 306, 326, 360, 395, 398, 404–405, 422
- drug-metabolizing enzymes, 63–64, 71, 223, 272, 281, 408, 430
- Drug monitoring, 23
- Drug response, 3, 23–24, 64, 83, 87, 110–111, 140, 144, 146, 148–149, 152–153, 159, 168, 216, 272, 326, 360–362, 395–396
- E**
- Electrocardiographic (ECG), 316, 382
- Electrophoresis, 25, 195, 201, 202, 207, 456
- Endothelin 1 (ET1), 128, 154
- Entrez, 5–7, 17
- Environmental Genome Project (EGP), 10, 12
- Enzyme Commission (EC), 5
- Enzyme-linked immunosorbent assay (ELISA), 448, 478
- Epidemiology, 89, 272
- Epidermal growth factor receptor (EGFR), 438–439
- Epigenetic, 22, 187–189, 191–194, 199, 209, 222, 233–234, 270, 272, 441
- aberrations, 188–189, 192
- Epstein Barr virus, 160, 439
- Erlotinib, 439
- Etanercept (ETN), 425, 430
- Ethnic differences, 282–283
- European Bioinformatics Institute (EBI), 14
- Exon splicing enhancer (ESE), 385
- Expression-Based SNP Imagemaps, 9–10
- F**
- Familial hypocalciuric hypercalcemia (FHH), 109, 113, 116–117, 119
- Familial male precocious puberty, 112, 123
- Fasta, 9–10
- Fatty acid transport protein 1 (FATP-1), 382
- Fingerprinting, 25, 189
- Fluorescence resonance energy transfer (FRET), 50
- Follicle-stimulating hormone, 109, 121
- follicle-stimulating hormone receptor (FSHR), 112, 121
- Food and Drug Administration (FDA), 2, 42, 71, 216, 438, 470
- Formulation, 22, 453, 470
- Functional dyspepsia, 406
- Functional genomics, 2, 213, 216, 222, 250, 255, 259, 271–272, 299, 379, 470
- G**
- G protein-coupled receptor (GPCR), 77–79, 81–82, 88, 110–114, 129, 139, 158, 162, 166
- activator of G protein signaling (AGS), 77, 86, 98
- G protein associated with asthma (GPRA), 109, 111, 113, 129
- G protein-coupled receptor kinases (GRKs), 77, 83, 91, 95, 97–98, 114
- regulator of G protein signaling (RGS), 77, 82, 87
- Gain of function, 81, 95–96, 111, 117, 119–120, 140, 162, 165, 233, 239
- Gametogenesis, 121–122
- Gastroesophageal reflux disease, 276, 395–396, 406
- Gastrointestinal disorders, 325, 395, 405
- carcinoma, 160
- Gefitinib, 44, 439
- GenBank, 5, 9
- Gene Expression Omnibus, 14
- Gene expression profiling, 22, 26
- Gene Ontology (GO), 5
- Gene silencing, 270–271
- Genetic association, 17–18, 31, 36, 189, 250, 362–363, 383
- GeneView, 9, 12
- Genomic control (GC), 36
- Genotype, 16, 255, 302–304, 363
- genotyping, 26, 46, 383, 419, 442
- GENSCAN, 6, 8
- Germline, 440
- Gilbert's syndrome, 67

Glucocorticoid receptor, 190, 283, 360, 367–368, 400  
 Glycosylation, 79, 219, 239, 248  
 Gonadotropin-releasing hormone (GnRHR), 109, 124  
 Guanosine triphosphatase (GTPase), 82, 84

## H

Haplotype, 162, 380, 419, 430, 441  
 HaploView, 362  
 HapMap, 9–10, 16, 361–362, 431  
 Heat shock organizing protein (Hop), 368  
 Heat shock protein, 248, 368, 426  
   heat shock protein 40 (Hsp40), 368  
   heat shock protein 70 (Hsp70), 269, 368  
   heat shock protein 90 (Hsp90), 269, 368  
 HEK293 cells, 51, 53, 240  
 HeLa cells, 52  
 Helicobacter pylori infection, 396, 406  
 Herpes simplex virus (HSV), 160  
 Hirschsprung's disease, 112, 128  
 Homology, 5–6, 8–10, 84, 95, 116, 383–384  
 Human Gene Mutation Database (HGMD), 9–10  
 Human Genome Database (GDB), 18  
 Human Genome Variation Society (HGVS), 9–10  
 Human immunodeficiency virus (HIV), 24, 50, 157  
 Human Protein Reference Database (HPRD), 13  
 Hydroperoxyeicosatetraenoic acid, 366  
 Hypercalcemia, 116  
 Hypercalciuria, 117, 119, 142  
   hypocalcemic, 117  
 Hypertension, 17–18, 87–88, 97, 142, 162  
 Hypocalcemia, 116–117  
 Hypoparathyroidism, 117, 119  
 Hypophysectomized, 121–122

## I

Idiopathic hypogonadotropic hypogonadism (IHH), 109, 112, 124  
 Immunity, 157, 401  
 Immunization, 262, 266–267, 451–453  
 Immunophilins, 368  
 Immunoprecipitation, 194, 198, 207  
 Infectious diseases, 18, 470  
 Infertility, 122  
 Inflammation, 155–156, 159, 161, 236, 266, 299, 359–360, 366–367, 448, 469–470, 472

Inflammatory bowel disease, 24, 395, 398, 400, 406  
 Infliximab (INF), 401, 425, 430  
 Inosine triphosphate pyrophosphatase, 399  
 Interaction, 15, 154, 307  
   drug–drug interactions (DDIs), 23, 64, 217, 283, 325–326  
   protein–protein interaction, 4, 14  
 Interleukin (IL), 159, 219–220, 426, 430  
 Internalization, 93–94  
 Irinotecan, 43–45, 67, 407  
 Irritable bowel syndrome, 401, 406  
 Isolated glucocorticoid deficiency (IGD), 112, 125

## K

Kallmann syndrome, 124  
 Kaposi sarcoma (KS), 159  
   Kaposi herpes virus, 159  
 Knockout mice, 53–54, 89, 121, 314, 385  
 Kyoto Encyclopedia of Genes and Genomes (KEGG), 4, 12–13

## L

Leukotriene, 153, 360, 365  
   leukotriene C4 synthase (LTC4 synthase), 366  
 Linear regression, 37  
 Linkage disequilibrium (LD), 32, 46, 65, 89, 143, 155, 163, 233, 314, 362, 383, 396, 428  
 Liquid chromatography/mass spectrometry (LC-MS), 51  
 Literature network, 463  
 Liver, 229, 280, 290, 300, 312  
   transplantation, 395, 402–403, 405–406  
 Loss of function, 81, 85, 110, 112–113, 127, 150, 165, 167, 233, 239  
 Luteinizing hormone, 109, 111–112, 123  
 Lymphocyte, 259, 298, 300, 455–456

## M

Major histocompatibility complex (MHC), 425–426, 430  
 MapView, 9, 11  
 Mass spectrometry, 26, 51  
 McCune–Albright's syndrome (MAS), 84, 87  
 MDCK, 50  
 Melanin-concentrating hormone (MCH), 120  
 Melanocortin, 112, 121

- Metabolizer, 27, 68, 284, 286, 315  
 extensive metabolizer (EM), 24  
 poor metabolizer (PM), 24, 68, 276  
 ultrarapid metabolizers (UMs), 213, 287,  
 289–290, 304
- Metabolomics, 255, 272
- Metabotropic glutamate (mGluR), 80
- Methotrexate, 44–45, 406, 414–415
- Methylenetetrahydrofolate reductase  
 (MTHFR), 23, 25, 219, 406, 414
- Methylome, 191, 193, 208
- Methylomics, 189
- Microarrays, 21, 25–27, 29, 223, 273, 326,  
 448, 450, 457, 471, 475
- MicroRNAs (miRNAs), 270
- Microsatellites, 35, 37, 223, 425–426,  
 428–430
- Microtubule-associated protein tau (MAPT), 245
- Modulators, 228, 263, 269
- Monoamine oxidase A (MAOA), 187–188,  
 192, 197, 207
- Monocarboxylate transporters (MCTs), 46
- Monogenic disease, 77, 109, 111, 122,  
 130, 140
- Motif, 6, 8–9, 91–92, 95, 113, 116, 127, 159,  
 166–167, 237, 244, 267, 368
- Motif Scan, 6, 8
- Multi-drug-resistance (MDR1), 23, 403–404
- Muscarinic receptors, 143, 226, 365
- Mutations, 81, 110, 115–116, 119–129, 160,  
 239–240, 242, 249, 255
- Myasthenia gravis (MG), 152, 162
- N**
- N-acetyltransferase 2 (NAT2), 23–24, 424
- NanoChip, 28
- National Center for Biotechnology  
 Information (NCBI), 5–6
- National Human Genome Research Institute  
 (NHGRI), 14
- Nephrogenic diabetes insipidus (NDI), 126
- Neurotransmitter, 141, 143–144, 149, 223,  
 233, 261
- Night blindness, 88, 112, 114, 141
- O**
- Obesity, 120–121, 162–163
- Oguchi disease, 88–90, 95–96, 115
- Oligoadenylate Synthetase Gene (OAS1), 389
- Oncology, 64, 72, 437
- Online Mendelian Inheritance in Man  
 (OMIM), 4, 17, 218
- Open reading frames (ORFs), 8, 222, 252
- Open Reading Frame Finder  
 (ORF Finder), 6, 8
- Opioids, 24, 284
- Organic anion transporting proteins (OATPs),  
 41, 46  
 OATP1B1, 43, 45–48, 50–53, 56–57  
 OATP1B3, 43, 45–50, 53, 56
- Organic cation transporters (OCTs), 46
- Ovarian dysgenesis, 112, 121–122
- Ovarian hyperstimulation syndrome  
 (OHSS), 122
- P**
- P-Glycoprotein (P-gp), 24, 42, 64, 69,  
 403, 416
- Parathyroid hormone (PTH), 85, 87, 109, 113,  
 116, 119  
 parathyroid hormone receptor 1 (PTHr1),  
 85, 119
- Pathogenesis, 233, 307
- Pathway, 13, 18, 365, 367
- Patterns, 2, 4, 8, 22, 85, 90, 140, 187,  
 189–191, 232, 255, 259, 300, 382, 466
- Peripheral blood mononuclear cells (PBMC),  
 87, 89, 152, 473
- Peroxisome proliferator-activated receptor  
 (PPAR), 382
- Personalized medicine, 2, 23, 141–142, 150,  
 153, 370
- Pfam, 4, 6, 8
- Pharmacodynamics, 22, 63, 65, 214, 216–217,  
 274, 293, 397
- Pharmacogenetics, 22, 41, 139–141, 143, 149,  
 153–154, 274, 359–360, 362, 365, 395,  
 414, 420–421, 423–425, 429, 431,  
 437–438
- Pharmacogenomics, 1–3, 5, 12, 21, 23, 63–64,  
 77–78, 125, 140, 152, 213, 271–272,  
 324, 379, 395, 413, 447, 469
- Pharmacokinetics, 15, 22, 42, 46, 51, 53–55,  
 57, 63, 65, 69–71, 216, 397
- Pharmacotherapy, 69
- Phenotypes, 83, 116, 119, 287  
 hemodynamic, 287, 314  
 phenotypic profiles, 256, 288, 300, 314
- Phospholipase C (PLC), 83–84, 156
- Phosphorylation, 92, 96–97, 114–115,  
 243, 268
- Pituitary somatotrophs, 84
- Platelet-activating factor (PAF), 159  
 platelet-activating factor receptor  
 (PAFR), 159

Pleiotropy, 188–189  
 Polyacrylamide, 193, 195, 201–203  
 Polygenic inheritance, 188–189  
 Polymerase chain reaction (PCR), 27, 49–50,  
     191, 195, 197, 203, 205, 207, 390–391,  
     440, 450  
 Polymorphisms, 10, 51, 53, 63, 71, 89, 97,  
     142, 146–152, 157–159, 163, 281, 369,  
     397, 403, 415, 425–426, 428  
 PolyPhen, 9–10  
 Population structure, 31–38  
 PredictProtein, 6, 8  
 Presenilins, 237, 239  
 Pro-opiomelanocortin (POMC), 121  
 Promoter, 112, 164–166, 199, 385  
 PROSITE, 4, 6, 8  
 Prostaglandin D<sub>2</sub> (PDG2), 155  
     prostaglandin D<sub>2</sub> receptor (DP), 155  
 Protease-activated receptors (PARs), 161  
 Proteasome, 253, 269  
 Protein Data Bank (PDB), 4, 6  
 Protein kinase A (PKA), 90, 155, 248  
 Protein kinase C (PKC), 90  
 Proteomics, 2, 255, 272  
 Proton, 396–397, 406  
 Pseudopseudohypoparathyroidism (PPHP),  
     85, 87  
 PSORT, 13–14  
 Psychiatric disorders, 144, 187–189, 191,  
     193–194, 204, 209  
 Psychiatry, 188, 193  
 Purinergic (P2RY12), 109, 113, 129

**Q**

Quantitative Multiplex MSP (QM-MSP), 195,  
     197, 204–207, 209–210  
 Quantitative structure–activity relationship  
     (QSAR), 15–16

**R**

R (PSMIX), 38  
 Reactome, 13  
 Reelin (RELN), 191–194, 197, 205, 209  
 REMARK guidelines, 443  
 Retinitis pigmentosa, 112, 114  
 Rheumatoid arthritis, 413, 420, 423,  
     425, 429  
 Rhodopsin, 79, 88, 95–96, 111–112, 114–115,  
     145, 147, 154  
 RNA interference (RNAi), 224, 241, 261,  
     270, 384  
 RxList, 14–15

**S**

Salmeterol, 360, 363  
 Sample source, 439–441  
 Scanning, 199  
 Schizophrenia (SCZ), 146, 148, 163–165,  
     188, 191–194  
 Secondary structure, 8  
     protein, 6, 8  
     RNA, 6, 8  
 Secretase, 220, 224, 234–235, 238–243,  
     261–266, 310  
 Self-organizing map (SOM), 453, 461  
 Sequencing, 25, 48–49, 193, 195–197,  
     199–200, 202–204, 442  
 Serotonin (5-HT), 148, 190, 209, 227, 261,  
     401–402, 406  
     receptor, 147–148  
 Signaling, 77–78, 80–91, 110–111, 114–115,  
     141, 147–151, 154–157, 160–161,  
     191–192, 237–243, 248, 263–265, 268,  
     307–308  
     signal transduction, 29, 81, 96, 265  
 Single nucleotide polymorphism (SNP), 4–5,  
     8–12, 16, 18, 26, 47, 87–88, 113, 144,  
     153–155, 167, 231–232, 361–362,  
     383–385, 387–391, 416–417, 419, 421,  
     429–430, 442  
     SNP-Fasta, 9–10  
 Single-base extension (SBE), 26  
 Skeletal dysplasias, 119–120  
 Software, 5–6, 14–16, 362, 384, 451–453,  
     459–460, 462–463, 466  
 Statistical, 33, 57, 67, 361, 442–443  
     adjusted test statistic, 36  
     statistics, 9, 444  
 Sulfasalazine, 414, 424–425  
 SWISS-MODEL, 4, 6  
 System for Integrative Genomic  
     Microarray Analysis (SIGMA),  
     17–18  
 Systems biology, 1–3, 5, 7, 18

**T**

Tacrolimus, 43–44, 403–406  
 Tamoxifen, 43, 65, 277–278  
 Testotoxicosis, 123  
 Therapeutic response, 291–293, 300–301,  
     306, 315, 317, 319  
 Thiopurine methyltransferase (TPMT), 67–69,  
     214, 274, 422–423  
 Three-dimensional (3-D), 6, 223  
 Thrombin, 161, 168  
 Thromboxane receptors, 155

- Thyroid, 84–85, 87, 113, 115, 116  
disease, 113, 115
- Thyrotropin (TSH), 85, 111, 115, 123  
TSH receptor (TSHR), 113, 115–116
- Toxicity, 53–55, 57, 64, 67–68, 71–72,  
236–237, 404–406, 417–420, 422–424,  
438, 447–448
- Transaminase, 290–291, 306
- Transcriptome, 22, 29
- Transcriptomics, 272
- Transmembrane (TM), 78–80, 118, 145, 147,  
154, 234, 415
- Transmission disequilibrium test (TDT), 35
- Transport, 41–42, 47, 50–57, 238–239, 245,  
415–416  
drug transporters, 57, 63–64, 69,  
71, 272
- Treatment, 22–25, 50, 54–57, 65–71, 143,  
260, 273, 280, 291–293, 300–301,  
310–311, 315–317, 319–324, 363,  
365–368, 380, 400–402, 416,  
424–425, 427, 438–439  
multifactorial, 291–292, 315, 317,  
319, 323
- Tumor, 439–441, 443–444
- Tumor necrosis factor (TNF),  
219–220, 426  
antagonists, 425
- Tyrosine hydroxylase (TH), 188,  
191, 196
- U**
- Ubiquitin, 223, 236–237, 240, 249–255,  
269–270
- Untranslated region (UTR), 89, 143–144,  
155, 421
- Uridine diphosphate glucuronosyltransferase  
(UGT), 63–64, 66  
UGT1A1, 23–24, 66–67, 404, 438–439
- V**
- Vaccination, 261, 267, 472, 477
- Variant, 32–33, 53, 55–56, 65, 70, 78, 83–84,  
87–89, 110–114, 116, 122–127,  
141–143, 145, 147–154, 156–159,  
161–168, 249–250, 285–287, 318,  
385–386, 390–391, 397, 399, 404,  
421, 431, 438
- Very large scale immobilized polymer  
synthesis (VLSIPSTM), 25
- Vitamin K epoxide reductase complex 1  
(VKORC1), 24, 28
- W**
- Warfarin, 24, 28, 276, 278
- X**
- Xenopus laevis*, 53